Loading
A phase 3 trial of Ivosidenib in sarcomas, run by Servier Bio-Innovation LLC, now recruiting.
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen is a phase 3 interventional study registered as NCT06127407 by Servier Bio-Innovation LLC, with 136 participants planned, started 2024-07-09 and due to reach its primary completion in 2028-02-01. Interventions recorded: Ivosidenib 500mg and Placebo.
Shares IDH inhibitors, Servier, Ivosidenib, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET) and the tag pipeline.
Shares IDH inhibitors, Servier, Ivosidenib, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET) and the tag pipeline.
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Small-molecule kinase inhibitors and the tag pipeline.
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Small-molecule kinase inhibitors and the tag pipeline.
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Small-molecule kinase inhibitors and the tag pipeline.
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Small-molecule kinase inhibitors and the tag pipeline.
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Small-molecule kinase inhibitors and the tag pipeline.
Shares Sarcomas (soft tissue, bone, GIST), Small-molecule kinase inhibitors and the tag pipeline.